Evidence is stronger than you think: a meta-analysis of vitamin C use in patients with sepsis

Jing Li

Abstract

Two recent publications by Sheikh and Horner and Teng et al. reviewed studies on incorporating vitamin C to treat septic patients; however, a meta-analysis was not offered in either report. This commentary extends both reviews by integrating a meta-analysis and sharing aggregated results. Pooled analyses demonstrated a marked reduction in mortality and duration of vasopressor administration in the group with the use of vitamin C.

Keywords: Sepsis, Severe sepsis, Sepsis management, Vitamin C, Ascorbic acid, Meta-analysis

Background

Sepsis is a severe condition with high mortality rates. Sheikh and Horner [1] and Teng et al. [2] recently published review articles regarding the incorporation of vitamin C in the treatment of sepsis. While the reviews offered insightful appraisals regarding the original studies and reported them in perspective, a meta-analysis was not produced and therefore aggregated quantitative results were not available for review. Considering both reviews were recent publications, this commentary extends their work by performing a meta-analysis and demonstrating the pooled results.

Main text

Sheikh and Horner [1] conducted a literature search of EMBASE, Medline, and PubMed through January 2018 surrounding sepsis and intravenous vitamin C; Teng et al. [2] completed a review of the literature using PubMed in terms of sepsis and vitamin C. Teng et al. summarized five pertinent papers in their review; however, two of the original articles described in their review, one written by Fowler et al. [3] and the other by Natarajan et al. [4], were derived from the same clinical trial. In addition, the study reported by Tanaka et al. concerned patients with burns [5]. Although the authors reasoned that most deaths in modern burn centers are from septic shock [5], this paper was deemed irrelevant for the review and meta-analysis on sepsis and vitamin C. After removing one of the duplicate studies—the Natarajan et al. paper—and the Tanaka et al. paper, the three studies summarized by Teng et al. matched those of Sheikh and Horner. A search of EMBASE and PubMed similar to that of Sheikh and Horner was performed on 8 June 2018, but no further full-text articles were found; therefore, the three papers reviewed by Sheikh and Horner were included in the meta-analysis.

Table 1 describes the characteristics of the included studies and assesses the quality and potential biases of each study. Even though all three studies looked at treating septic patients with vitamin C, the quality of results varied due to differences in study design, inclusion criteria, and sample size. The studies by both Fowler et al. [3] and Zabet et al. [6] were randomized, double-blind, placebo-controlled clinical trials of small sample sizes, while the Marik et al. study [7] was a before-after study with propensity score adjustment. It is worth noting that Marik et al. included intravenous hydrocortisone and thiamine, in addition to vitamin C, thereby introducing confounders into the study [7]. Three clinical outcomes were reported by at least two articles, which were mortality, intensive care unit length of stay (ICU-LOS), and vasopressor duration [3, 6, 7].

A meta-analysis was performed on these three outcomes using Comprehensive Meta-Analysis (version 3.3.070). Considering diversity in the study populations and differences in the treatments including varying doses of vitamin C, a random-effects model was used in all analyses. Mortality was considered the primary outcome for this meta-analysis, and a fail-safe N test was carried out.
Table 1 Characteristics of included studies

| Study         | Year | Design                  | n  | Inclusion criteria                                                                 | Exclusion criteria                                                                 | Participant characteristics | Dose of vitamin C          | Outcomes reported                                      | Quality assessment                                                                 |
|---------------|------|-------------------------|----|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|----------------------------|---------------------------|--------------------------------------------------------|------------------------------------------------------------------------------------|
| Marik et al.  | 2017 | Retrospective before-after study | 94 | Primary diagnosis of severe sepsis or septic shock and a procalcitonin level ≥ 2 ng/mL | < 18 years, pregnant, or with limitations of care                                   | Mean age for treated group 58.3 years, 57% male; mean age for control group 62.2 years, 49% male | 1.5 g IV every 6 h   | Hospital mortality, ICU-LOS, duration of vasopressors, RRT for AKI, reduction in serum procalcitonin and SOFA over the first 72 h | Neither randomized nor blinded, although propensity-adjusted; protocol included intravenous hydrocortisone and thiamine, in addition to vitamin C |
| Fowler et al. | 2014 | Prospective phase I trial | 24 | Diagnosis of severe sepsis                                                        | < 18 years, pregnant, prisoners, cognitively impaired and unable to provide consent, or non-English speakers | Age for treated group: 30–92 years, 56% male; age for control group: 54–68 years, 50% male | 50 mg/kg/day, or 200 mg/kg/day | Vitamin C safety and tolerability, days on vasopressor, ventilator-free days, ICU-LOS, 28-day mortality | Randomized, double-blind, placebo-controlled, but underpowered                     |
| Zabet et al. | 2016 | Prospective clinical trial | 28 | Adult (18–65 years) with diagnosis of septic shock and required vasopressor drug to maintain MAP > 65 mmHg |                                                                                     | Mean age for treated group 64.14 years, 71% male; mean age for control group 63.71 years, 79% male | 25 mg/kg IV every 6 h | Vasopressor dose and duration, ICU-LOS, 28-day mortality | Randomized, double-blind, placebo-controlled, but small sample size |

AKI: acute kidney injury; ICU-LOS: intensive care unit length of stay; IV: intravenous; MAP: mean arterial pressure; RRT: renal replacement therapy; SOFA: Sepsis-Related Organ Failure Assessment
out to assess publication bias. Fowler et al. randomized patients into three groups: low-dose ascorbic acid, high-dose ascorbic acid, and placebo [3]. The low-dose and high-dose groups were combined into the vitamin C group for meta-analysis. If the original study did not incorporate a power analysis or mention a one-sided or two-sided test, a two-sided test was assumed.

All three studies reported mortality rates between the experimental arm with the use of vitamin C and the control arm without vitamin C. While the mortality results from two studies [6, 7] favored the vitamin C treatment at the significance level of 0.05, the study by Fowler et al. [3] did not reach statistical significance. Pooled analysis of all three studies revealed a marked reduction in mortality with the use of vitamin C (odds ratio (OR) $= 0.17$, 95% confidence interval (CI) $0.07–0.40$; $p < 0.001$; Fig. 1a). No significant heterogeneity between studies was found ($I^2 = 0$; $p = 0.40$ for Cochran’s $Q$). Due to the strong effect size of two of the three studies, the computed fail-safe $N$ would require nine null-finding studies to render this pooled result non-significant at $\alpha = 0.05$.

All three studies reported ICU-LOS. Results from Marik et al. [7] and Zabet et al. [6] were incorporated in the meta-analysis; however, the study by Fowler et al. [3] was excluded as it did not provide either standard deviation (SD) for direct synthesis or the median for estimating SD [8]. Although Marik et al. reported median and interquartile range for ICU-LOS in their publication, the mean and SD were supplied by Dr. Marik via an email inquiry [7]. Pooled analysis favored the use of vitamin C, but statistical significance was not reached (standardized mean difference (SMD) = $-0.30$, 95% CI $-0.83$ to $0.23$; $p = 0.27$; Fig. 1b). Heterogeneity between these two studies was not significant ($I^2 = 42.3$%; $p = 0.19$ for Cochran’s $Q$).

All three studies reported the duration of vasopressor use. Results from Marik et al. [7] and Zabet et al. [6] were incorporated in the meta-analysis; however, the study by Fowler et al. [3] was excluded as it did not

| Study name          | Statistics for each study | Odds ratio and 95% CI |
|---------------------|---------------------------|-----------------------|
|                     | Odds ratio | Lower limit | Upper limit | p-Value |
| Marik et al. [7]    | 0.137      | 0.042       | 0.446       | 0.001   |
| Fowler et al. [3]   | 0.467      | 0.082       | 2.656       | 0.390   |
| Zabet et al. [6]    | 0.093      | 0.015       | 0.591       | 0.012   |
|                     | 0.170      | 0.072       | 0.404       | 0.000   |

| Study name          | Statistics for each study | Std diff in means and 95% CI |
|---------------------|---------------------------|-----------------------------|
|                     | Std diff | Standard error | Variance | Lower limit | Upper limit | Z-Value | p-Value |
| Marik et al. [7]    | -0.494   | 0.209          | -0.044   | -0.904     | -0.084     | -2.359   | 0.018   |
| Zabet et al. [6]    | 0.075    | 0.378          | 0.143    | -0.666     | 0.816      | 0.199    | 0.843   |
|                     | -0.297   | 0.271          | 0.073    | -0.827     | 0.234      | -1.095   | 0.274   |

| Study name          | Statistics for each study | Std diff in means and 95% CI |
|---------------------|---------------------------|-----------------------------|
|                     | Std diff | Standard error | Variance | Lower limit | Upper limit | Z-Value | p-Value |
| Marik et al. [7]    | -1.723   | 0.242          | 0.058    | -2.196     | -1.249     | -7.133   | 0.000   |
| Zabet et al. [6]    | -1.206   | 0.411          | 0.169    | -2.011     | -0.401     | -2.935   | 0.003   |
|                     | -1.571   | 0.235          | 0.055    | -2.033     | -1.110     | -6.675   | 0.000   |

**Fig. 1** Pooled analyses of mortality (a), ICU-LOS in days (b), and vasopressor duration in hours (c). ICU-LOS intensive care unit length of stay, CI confidence interval
provide either SD for direct synthesis or the median for estimating SD, and the duration was summarized in days while the other two studies reported hours [8]. Pooled analysis showed a significant reduction in duration of vasopressor administration in the group with vitamin C (SMD = −1.57, 95% CI −2.03 to −1.11; p < 0.001; Fig. 1c). Heterogeneity between these two studies was not significant (I² = 15.0%; p = 0.28 for Cochran’s Q).

Conclusions
Despite varying degrees of statistical significance between the original studies, this meta-analysis reveals a positive correlation between incorporating vitamin C in the treatment of sepsis and favorable patient outcomes, including better survival and shorter duration of vasopressor use; I² was shown to be insignificant, and therefore corroborates the consistency of evidence. Since this is a quantitative synthesis of a small number of studies, further randomized clinical trials are required to prove a causal relationship. If this relationship is confirmed, vitamin C has enormous potential to improve patient care and reduce mortality rates due to its low cost and wide availability.

Abbreviations
ICU-LOS: Intensive care unit length of stay; CI: Confidence interval; OR: Odds ratio; SD: Standard deviation; SMD: Standardized mean difference

Acknowledgements
The author would like to thank Isabella Zikakis for her assistance with editing the manuscript.

Funding
Publication costs for this article were funded by the author’s organization.

Availability of data and materials
All data can be found in the referenced articles or in the table and figure included in this article.

Author’s contributions
JL conceived the commentary, performed the meta-analysis, drafted, revised, and approved the manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The author declares that she has no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 30 August 2018 Accepted: 12 September 2018
Published online: 11 October 2018

References
1. Sheikh M, Horner D. Bet 2: does intravenous vitamin C improve mortality in patients with severe sepsis? Emerg Med J. 2018;35(4):272–4.
2. Teng J, Pourmand A, Mazer-Amirshahi M. Vitamin C: the next step in sepsis management? J Crit Care. 2018;43:230–4.
3. Fowler AA 3rd, Syed AA, Knowlson S, et al. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. J Transl Med. 2014;12:32.
4. Natarajan R, Fisher BJ, Syed AA, et al. Impact of intravenous ascorbic acid infusion on novel biomarkers in patients with severe sepsis. J Pulm Respir Med. 2014;14(6):2.
5. Tanaka H, Matsuda T, Miyagantani Y, et al. Reduction of resuscitation fluid volumes in severely burned patients using ascorbic acid administration: a randomized, prospective study. Arch Surg. 2000;135(3):326–31.
6. Zabet MH, Mohammadi M, Ramezani M, et al. Effect of high-dose ascorbic acid on vasopressor’s requirement in septic shock. J Res Pharm Pract. 2016;5(2):94–100.
7. Marik PE, Khangoora V, Rivera R, et al. Hydrocortisone, vitamin C, and thiamine or the treatment of severe sepsis and septic shock: a retrospective before-after study. Chest. 2017;151(6):1229–38.
8. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13.